Objective:Estradiol (E2) plays an important role in the development of breast cancer.In postmenopausal women,the estrogen can be synthesized via aromatase (CYP19) pathway and steroid-sulfatase (STS) pathway in peripheral tissues,when the production in ovary has ceased.The objective of our study was to explore the effects of Shu-Gan-Liang-Xue Decoction (SGLXD) on the expressions of CYP19 and STS in estrogen receptor positive breast cancer MCF-7 and T47D cells.Methods:The effects of SGLXD on the cell viability of MCF-7 and T47D were analyzed by MTT assay.By quantitative real-time RT-PCR and Western blot,we evaluated the mRNA and protein expressions of CYP19 and STS in MCF-7 and T47D cells after SGLXD treatment.Results:By MTT assay,the cell viability rates of MCF-7 and T47D were significantly inhibited by SGLXD in a dose-dependent manner,the IC50 values were 40.07 mg/ml for MCF-7 cells and 25.62 mg/ml for T47D cells,respectively.As evidenced by real-time PCR and Western blot,the high concentrations of SGLXD significantly down-regulated the expressions of CYP19 and STS both in the transcript level and the protein level.Conclusion:The results suggest that SGLXD is a potential dual aromatase-sulfatase inhibitor by simultaneously down-regulating the expressions of CYP19 and STS in MCF-7 and T47D cells.
